Adalvo is pleased to announce the restart of the EU Marketing Authorisation Approval for Empagliflozin 10mg and 25mg film-coated tablets with an anticipated approval date in July 2024.
Our product has been developed based on the reference brand Jardiance 25mg film-coated tablets, which is indicated in the treatment of type 2 diabetes mellitus.
The brand sold approximately $18.8bn globally in 2023, having a significant growth potential with Global 3Y CAGR at +24%, according to IQVIA.
Adalvo is one of the few companies having an extensive offering of both small molecule and peptide treatment possibilities for type 2 diabetes.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner up now!